H.C. Wainwright Sticks to Their Hold Rating for BioNTech SE

H.C. Wainwright analyst Robert Burns reiterated a Hold rating on BioNTech SE (NASDAQ:BNTX) on Wednesday, setting a price target of $48, which is approximately 3.96% below the present share price of $49.98.

Burns expects BioNTech SE to post earnings per share (EPS) of -$0.26 for the second quarter of 2020.

The current consensus among 5 TipRanks analysts is for a Moderate Buy rating of shares in BioNTech SE, with an average price target of $45.25.
The analysts price targets range from a high of $60 to a low of $36.

In its latest earnings report, released on 12/31/2019, the company reported a quarterly revenue of $27.99 million and a net profit of -$52.94 million. The company's market cap is $11.19 billion.

According to TipRanks.com, H.C. Wainwright analyst Robert Burns is a 5-star analyst with an average return of 34.5% and a 80.8% success rate.

BioNTech SE focuses on the development of molecular immune therapies and biomarker-based diagnostic approaches. The firm develops and manufactures biomarker-based in vitro diagnostic devices (IVDD) and commercializes products. It offers drug discovery services for therapeutic areas including infectious diseases, allergies and autoimmune disorders. The company was founded by Christopher Huber, Özlem Türeci and Ugur Sahin in 2008 and is headquartered in Mainz, Germany.